Other Clinical Trial - SHR-1316 in Combination With Chemotherapy in

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04797507` - SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer	Phase 2
Recruiting	`NCT04437212` - Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer	Phase 2
Recruiting	`NCT05323890` - Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.	Phase 2

See also

Status

Clinical Trial

Phase

Not yet recruiting

NCT04797507 - SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Phase 2

Recruiting

NCT04437212 - Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Phase 2

Recruiting

NCT05323890 - Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03732508
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Fei Shi
Phone	+86-18036618733
Email	hrshifei@163.com
Status	Recruiting
Phase	Phase 2
Start date	November 2018
Completion date	October 2020

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms